PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
תוכן מסופק על ידי NeurologyLive® Mind Moments®. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי NeurologyLive® Mind Moments® או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Player FM - אפליקציית פודקאסט
התחל במצב לא מקוון עם האפליקציה Player FM !
התחל במצב לא מקוון עם האפליקציה Player FM !
104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2
MP3•בית הפרקים
Manage episode 389645336 series 3340456
תוכן מסופק על ידי NeurologyLive® Mind Moments®. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי NeurologyLive® Mind Moments® או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
- 1:10 – Overview of post-hoc analysis of REST-ON
- 3:15 – Differences in type 1 and 2 narcolepsy
- 5:50 – Neurology News Minute
- 8:15 – Expanding treatment profile of once-nightly sodium oxybate
- 10:55 – Lingering unmet needs of patients with narcolepsy
- 11:20 – Realistic timeline of gene therapies for epilepsy
- 14:00 – Future of narcolepsy research, drug development trials
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis
ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study
FDA Clears NeuroOne’s OneRF Ablation System for Neurosurgerical Procedures
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
126 פרקים
MP3•בית הפרקים
Manage episode 389645336 series 3340456
תוכן מסופק על ידי NeurologyLive® Mind Moments®. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי NeurologyLive® Mind Moments® או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
- 1:10 – Overview of post-hoc analysis of REST-ON
- 3:15 – Differences in type 1 and 2 narcolepsy
- 5:50 – Neurology News Minute
- 8:15 – Expanding treatment profile of once-nightly sodium oxybate
- 10:55 – Lingering unmet needs of patients with narcolepsy
- 11:20 – Realistic timeline of gene therapies for epilepsy
- 14:00 – Future of narcolepsy research, drug development trials
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis
ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study
FDA Clears NeuroOne’s OneRF Ablation System for Neurosurgerical Procedures
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
126 פרקים
כל הפרקים
×ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.